Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake
- PMID: 29038268
- PMCID: PMC5740309
- DOI: 10.1128/AAC.01899-17
Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake
Abstract
The steps by which Escherichia coli strains harboring mutations related to fosfomycin (FOS) resistance arise and spread during urinary tract infections (UTIs) are far from being understood. The aim of this study was to evaluate the effects of urine, pH, and anaerobiosis on FOS activity against a set of isogenic strains carrying the most prevalent chromosomal mutations conferring FOS resistance (ΔuhpT, ΔglpT, ΔcyaA, and ΔptsI), either singly or in combination. We also studied fosfomycin-resistant E. coli clinical isolates from patients with UTI. Our results demonstrate that urinary tract physiological conditions might have a profound impact on FOS activity against strains with chromosomal FOS resistance mutations. Specifically, acidic pH values and anaerobiosis convert most of the strains categorized as resistant to fosfomycin according to the international guidelines to a susceptible status. Therefore, urinary pH values may have practical interest in the management of UTIs. Finally, our results, together with the high fitness cost associated with FOS resistance mutations, might explain the low prevalence of fosfomycin-resistant E. coli variants in UTIs.
Keywords: Escherichia coli; UTI; chromosomal mutations; fosfomycin activity; fosfomycin resistance; urinary tract infection.
Copyright © 2017 American Society for Microbiology.
Figures

Similar articles
-
Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.Int Urol Nephrol. 2015 Jul;47(7):1059-66. doi: 10.1007/s11255-015-1018-9. Epub 2015 May 31. Int Urol Nephrol. 2015. PMID: 26026972
-
Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.Acta Microbiol Immunol Hung. 2018 Mar 1;65(1):15-25. doi: 10.1556/030.64.2017.030. Epub 2017 Nov 15. Acta Microbiol Immunol Hung. 2018. PMID: 29137487
-
[In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].Mikrobiyol Bul. 2009 Oct;43(4):645-9. Mikrobiyol Bul. 2009. PMID: 20084918 Turkish.
-
An update on the management of urinary tract infections in the era of antimicrobial resistance.Postgrad Med. 2017 Mar;129(2):242-258. doi: 10.1080/00325481.2017.1246055. Epub 2016 Oct 21. Postgrad Med. 2017. PMID: 27712137 Review.
-
Why fosfomycin trometamol as first line therapy for uncomplicated UTI?Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:79-83. doi: 10.1016/s0924-8579(03)00231-0. Int J Antimicrob Agents. 2003. PMID: 14527776 Review.
Cited by
-
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature.Microorganisms. 2023 Nov 3;11(11):2699. doi: 10.3390/microorganisms11112699. Microorganisms. 2023. PMID: 38004712 Free PMC article.
-
Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.J Antimicrob Chemother. 2022 Apr 27;77(5):1324-1333. doi: 10.1093/jac/dkac045. J Antimicrob Chemother. 2022. PMID: 35211736 Free PMC article.
-
Fosfomycin Resistance Evolutionary Pathways of Stenotrophomonas maltophilia in Different Growing Conditions.Int J Mol Sci. 2022 Jan 20;23(3):1132. doi: 10.3390/ijms23031132. Int J Mol Sci. 2022. PMID: 35163052 Free PMC article.
-
Novel Chromosomal Mutations Responsible for Fosfomycin Resistance in Escherichia coli.Front Microbiol. 2020 Oct 20;11:575031. doi: 10.3389/fmicb.2020.575031. eCollection 2020. Front Microbiol. 2020. PMID: 33193186 Free PMC article.
-
Preserving the efficacy of antibiotics to tackle antibiotic resistance.Microb Biotechnol. 2024 Jul;17(7):e14528. doi: 10.1111/1751-7915.14528. Microb Biotechnol. 2024. PMID: 39016996 Free PMC article. Review.
References
-
- Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. 2010. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 16:184–186. doi:10.1111/j.1469-0691.2009.02921.x. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical